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Summary
To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endoge-
nous expression of Trp53R172H and KrasG12D to the mouse pancreas, revealing the cooperative development of invasive
and widely metastatic carcinoma that recapitulates the human disease. The primary carcinomas and metastases demon-
strate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion—
hallmarks of human carcinomas not typically observed in mice. No mutations were discovered in other cardinal tumor
suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to
PDA with different biological behaviors. These findings have clear implications for understanding mechanisms of disease
pathogenesis, and for the development of detection and targeted treatment strategies.S I G N I F I C A N C E
Cancer is a genetic disease driven by the stochastic acquisition of mutations and shaped by natural selection. Genomic instability,
a hallmark of human epithelial cancers, propagates these mutations, allowing cells to overcome critical barriers to unregulated
growth, and may therefore herald a defining event in malignant transformation. How and when during the course of tumor pro-
gression significant genomic instability arises, and whether a cancer can be cured or even contained after that point, represent
pivotal and largely unanswered questions. We describe here a murine model of pancreatic ductal adenocarcinoma, characterized
by the development of widespread and complex chromosomal instability, which may prove useful in investigating these issues.Introduction
Ductal adenocarcinoma of the pancreas (PDA) is an almost uni-
formly lethal disease, largely because it eludes diagnosis until
very advanced stages. Indeed, greater than 80% of patients
with PDA have locally unresectable or frankly metastatic dis-
ease at the time of presentation (Warshaw and Fernandez-del
Castillo, 1992; Yeo et al., 2002b). PDA is also unusually resis-
tant to all forms of cytotoxic chemotherapies and ionizing radi-
ation, and as a result, as many people die of PDA each year
as are newly diagnosed with it. Now the fourth leading cause of
cancer-related mortality among men and women in the United
States, approximately 31,000 new cases and deaths were ex-
pected from PDA in 2004 (Jemal et al., 2004).
The current standard of care for advanced PDA is infusional
gemcitabine, a deoxycytidine analog and inhibitor of nucleic
acid synthesis, which prolongs survival by only a few weeks
and provides symptomatic improvement in a minority of pa-
tients (Burris et al., 1997). For those rare patients able to un-CANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.dergo complete surgical resection of their primary tumor, five-
year survival can be as high as 20%–40%; however, even
these highly selected patients eventually succumb to both lo-
cally recurrent and metastatic disease (Allison et al., 1998; Yeo
et al., 2002a). Thus, in addition to methods to detect preinva-
sive disease, therapies that can kill invasive and metastatic
pancreatic cancer cells are needed.
Considerable insight into potential mechanisms of disease
pathogenesis has been gleaned from static analyses of re-
sected pancreatic tumor specimens giving rise to histologic
(Brat et al., 1998; Hruban et al., 2001a; Klimstra and Long-
necker, 1994) and molecular (Hruban et al., 2000; Hruban et
al., 2001b) frameworks for disease progression. These studies
of sporadic pancreatic cancers have suggested a model of dis-
ease evolution through a preinvasive state, termed pancreatic
intraepithelial neoplasia (PanIN), involving progressive cellular
and architectural atypia accompanied by increasingly frequent
mutations in a key oncogene and select tumor suppressorDOI 10.1016/j.ccr.2005.04.023 469
A R T I C L Egenes (TSG). Specifically, activating point mutations in the
KRAS2 proto-oncogene are encountered in greater than 90%
of pancreatic carcinomas, along with inactivation of the
CDKN2/INK4A locus in a similar number. Point mutations of
the TP53 tumor suppressor have been described in approxi-
mately 75% of pancreatic cancers, while 55% harbor deletions
or mutations in SMAD4 (also known as DPC4 and MADH4).
BRCA2 is mutated in less than 10% of sporadic pancreatic
cancers and perhaps as many as 19% of familial cases (Hahn
et al., 2003; Murphy et al., 2002). Mutations in DNA mismatch
repair genes, such asMSH2 andMLH1, similarly occur in fewer
than 10% of cases. Interestingly, such mutations are found in
rare tumors with a distinct syncytial growth pattern, and are
not associated with KRAS2 or TP53 mutations (Goggins et al.,
1998; Yamamoto et al., 2001). Ductal adenocarcinomas of the
pancreas also manifest an unusual degree of numerical and
structural chromosomal instability (reviewed in Hansel et al.,
2003).
The genetic epidemiology described above has richly in-
formed attempts to model the disease in animals (reviewed in
Leach, 2004). However, such molecular compendia are neces-
sarily speculative and cannot distinguish causal from coinci-
dent events, nor which combinations of events might be re-
quired to establish disease. Corroborative support for the
involvement of certain tumor suppressor genes in disease
pathogenesis is provided by a number of heritable syndromes
that substantially increase the lifetime risk of pancreatic cancer,
as seen, for example, in FAMMM syndrome patients possess-
ing germline CDKN2/INK4A mutations and in Li-Fraumeni pa-
tients with germline TP53 mutations. Definitive evidence can
be provided by engineering these events systematically into
the mammalian genome and observing the resultant pheno-
type. By this means, we now know that endogenous expres-
sion of oncogenic KrasG12D serves to intiate PanIN, which can
spontaneously progress to fully invasive and frankly metastatic
disease (Hingorani et al., 2003). The molecular details of dis-
ease progression remain largely unknown, although some con-
clusions have recently been established. When placed in the
context of concomitant biallelic Ink4a/Arf deletion, mice ex-
pressing endogenous KrasG12D developed an aggressive, lo-
cally invasive, and poorly differentiated disease accompanied,
on occasion, by microscopic metastases (Aguirre et al., 2003).
Interestingly, these tumors did not manifest mutations in any of
the other TSG pathways noted above. This raises the question
of whether other TSG mutations alter the biology of the dis-
ease. For example, additional mutations may be required to
develop a significant metastatic burden. Alternatively, the abro-
gation of each TSG pathway individually may constitute a dis-
tinct genetic route to PDA with a potentially unique phenotype.
To directly address questions concerning the requirements
for tumor progression, we have targeted endogenous expres-
sion of Trp53R172H, an ortholog of one of the most common
TP53 mutations in human PDA (Olivier et al., 2002), to progeni-
tor cells of the mouse pancreas. We find that physiologic ex-
pression of Trp53R172H, in the context of concomitant endoge-
nous KrasG12D expression, promulgates the development of
invasive and widely metastatic pancreatic ductal adenocarci-
noma that recapitulates the principal clinical, histopathological,
and genomic features of the cognate human condition.470Results
LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice
develop metastatic PDA
We have previously described the targeting of endogenous
KrasG12D to the mouse pancreas (Hingorani et al., 2003). Using
similar methods, we have generated a conditionally expressed
point mutant allele of the Li-Fraumeni human ortholog,
TP53R175H (Figure 1 and Olive et al., 2004). Activation of both
the KrasG12D and the Trp53R172H alleles occurs in tissue pro-
genitor cells of the developing mouse pancreas through inter-
breeding with Pdx-1-Cre transgenic animals. The presence of
each rearranged, activated allele can be detected in the
pancreata, but not tails, of compound mutant animals by spe-
cific PCR (Figure 1). Thus, tissues not expressing Cre recombi-
nase remain functionally heterozygous for these loci. We note
that activation of the respective point mutant alleles occurs in
the context of expression of their wild-type counterparts, as is
presumably encountered in the spontaneous acquisition of
such mutations in the human disease.
LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice have a
dramatically shortened median survival of approximately 5
months as compared with their control littermates (wild-type,
Pdx-1-Cre and LSL-Trp53R172H/+;Pdx-1-Cre animals). In the tri-
ple mutant cohort (n = 28), 100% mortality occurred by 12
months (Figure 1B); only one animal lacked invasive PDA at
necropsy (Table 1). As expected from previous analyses of
Trp53+/− animals (Donehower et al., 1992; Jacks et al., 1994),
thymic lymphomas (n = 2) or teratocarcinomas (n = 1) were
also rarely found at necropsy. Triple mutant animals also suc-
cumb much earlier than LSL-KrasG12D/+;Pdx-1-Cre animals,
which spontaneously develop PDA with a proscribed latency
after manifesting preinvasive disease. The majority of LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre animals develop cachexia
and abdominal distension, highly reminiscent of clinical find-
ings seen in the human disease (Figure 2A). From the time of
development of abdominal distension, reflecting the accumula-
tion of hemorrhagic ascites, imminent demise is rapid and pre-
dictable, typically occurring within 48–72 hr. Upwards of 7 milli-
liters of ascitic fluid could be recovered from these animals. At
necropsy, a large, firm, fibrotic head-of-the-pancreas tumor
was almost invariably seen (Figures 2B and 2E), frequently ac-
companied by signs of biliary and small bowel obstruction (Fig-
ures 2B and 2C), reflecting compression and invasion of ad-
jacent structures, respectively, classic features of human
pancreatic cancer. The remainder of the pancreas was typically
multinodular (Figure 2C). Metastatic foci could be readily ap-
preciated studding the surface of the liver (Figures 2D and 2E),
lungs (Figures 2D and 2F), diaphragm, and adrenals (not
shown) in many animals; in addition, although not systemati-
cally evaluated in all cases, metastatic spread to peripancrea-
tic, mesenteric, and retroperitoneal lymph nodes was noted in
several of the mice (Table 1). The specific distribution of meta-
static disease also recalls that of human PDA, in which metas-
tases are frequently encountered to the liver (80%), lung (50%–
60%), adrenals (20%), and peritoneum (20%–30%) (reviewed
in Lillemoe et al., 2000).
In very young LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre
mice (e.g., 4–6 weeks), the vast majority of the pancreatic pa-
renchyma was histologically normal, characterized by abun-
dant acinar tissue and scattered islets. Early stage PanINCANCER CELL : MAY 2005
A R T I C L EFigure 1. Targeting endogenous KrasG12D and Trp53R172H expression to the mouse pancreas
A: Endogenous alleles of KrasG12D and Trp53R172H are conditionally activated in the pancreata of LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (triple mutant)
mice. Specific PCR analysis of genomic DNA from the pancreata, but not the tails, of triple mutant mice reveals the expected “1LoxP” recombination
product for each targeted allele.
B: Survival of LSL-KrasG12D/+;LSL- Trp53R172H/+;Pdx-1-Cre mice is significantly decreased. Kaplan-Meier curves reveal a median survival in triple mutant mice
of approximately 5 months, significantly less than wild-type (WT), LSL-Trp53R172H/+;Pdx-1-Cre, and LSL-KrasG12D/+;Pdx-1-Cre mice (p < 0.001, log-rank test, for
each pairwise combination).lesions in these young animals, with demonstrated rearrange-
ment of the mutant alleles, were observed infrequently (data
not shown). A similar stage and degree of disease burden oc-
curs in animals expressing only endogenous KrasG12D (Hingor-
ani et al., 2003). Thus, invasive tumors did not appear to de-
velop in utero or even in the immediate postnatal period, a
latency that suggests the requirement for additional genetic
events for disease progression.
A significant disease burden did become apparent in animals
by 10 weeks of age at the earliest. Importantly, the full spec-
trum of preinvasive lesions was apparent in these mice (Figure
2G and data not shown). Histologic analyses of primary pan-
creatic carcinomas from triple mutant animals revealed a pre-
dominant moderately well-differentiated to well-differentiated
morphology organized in a glandular architecture (Figure 2H) in
the majority of mice (n = 22/25; Table 1), as is observed in the
human disease. The carcinomas expressed CK-19 (Figure 2O)CANCER CELL : MAY 2005and frequently contained mucin, as demonstrated by Alcian
blue staining (Figure 2N). Metastases to the liver (Figures 2I
and 2J) and lungs (Figures 2K and 2L) were morphologically
similar to the pancreatic primaries.
Some tumors also contained minor, poorly differentiated, or
undifferentiated components with anaplastic (n = 7/25; Supple-
mental Figure S1A) or sarcomatoid features (n = 2/25; Supple-
mental Figures S1B and S1C). Noninvasive cystic papillary
neoplasms (n = 3/25; Supplemental Figure S1D) were occa-
sionally noted, as were areas of focal adenosquamous mor-
phology (n = 3/25, Supplemental Figures S1E and S1F), an un-
common form of human pancreatic ductal cancer comprising
3%–4% of reported cases (Kardon et al., 2001). Finally, several
animals developed esophageal papillomas (Supplemental Fig-
ure S1G) and hyperplasias, or papillomatosis, of the biliary tree
(Supplemental Figures S1H and S1I), likely reflecting expres-
sion of Pdx-1 in the developing foregut endoderm.471
A R T I C L ETable 1. Clinical spectrum of disease in LSL-KrasG12D/+;LSL- Trp53R172H/+;Pdx-1-Cre mice
Histology
ID Age (days) PDA 1° 2° Liver Lung Diaphragm Adrenal Ascites Other
1 150 Y G YM YM Ym Ym Y HCC
2 89 N NA N N N N N TL
3 132 Y G YM N N Ym N NSCLC
4 137 Y G Ym YM N N Y NPm
5 85 * * * * * * * *
6 92 Y G U YM YM N N Y
7 170 Y G YM YM Ym Ym Y Mm
8 174 Y G N ND N N N
9 147 Y ND YM YM N N N
10 240 Y G YM YM YM N Y BP
11 230 Y S G N N Ym N N pLN, NSCLC
12 186 Y G AS YM YM N N N HCC, BP
13 175 Y G YM N YM N Y
14 47 Y CPN YM N YM N Y Teratocarcinoma
15 340 Y G N N N N N BP
16 281 Y G N N N N N
17 295 Y G U YM YM YM Ym Y RM
18 149 Y G AS YM N YM N N
19 71 Y G U, CPN N YM N N Y
20 101 Y G U, CPN N N N N Y
21 158 Y G U N N N N N TL, BP
22 276 Y G N N YM N Y pLN
23 239 Y G U YM N N N N Rm, pLN, SN
24 133 Y G N N N N Y
25 355 Y G AS YM YM YM YM Y Rm, BP
26 286 Y G U YM N N N Y Mm, Rm
27 232 Y G YM YM N YM Y pLN, Mm, RM, mLN, LNm
28 249 Y S G Ym N N N Y mLN
Totals 26/27 17/27 11/25 10/27 6/27 16/27
% 96.3 63.0 44 37 22.2 59.3
M, macrometastasis; m, micrometastasis; A, adrenal capsule; TL, thymic lymphoma; NP, nervous plexus; M, mesentery; R, renal capsule; pLN, peripancreatic lymph
node; mLN, mediastinal LN; ND, not determined; *, tissue not evaluable secondary to necrosis; 1°, predominant pancreatic histology noted (present in >50% of
evaluated tissue); 2°, secondary pancreatic histologies noted; G, glandular; U, undifferentiated; S, sarcomatoid; CPN, cystic papillary neoplasm; AS, adenosquamous;
HCC, hepatocellular carcinoma; BP, biliary papillomatosis; NSCLC, non-small cell lung cancer; SN, spindle cell neoplasm.Molecular heterogeneity of tumor progression
To characterize events of potential importance in tumor pro-
gression, we began by assessing the expression patterns of
proteins in critical signaling pathways. Pancreatic tumorigene-
sis has been frequently associated with overexpression of
members of the Erbb family of receptor tyrosine kinases and
their associated ligands (Hansel et al., 2003). In particular, in-
creased expression of Errb1/Egfr and Errb2/Her2 has been
noted, and these receptors have even been suggested as po-
tential therapeutic targets for the disease. We surveyed a large
number of preinvasive, invasive, and metastatic lesions for ex-
pression of these receptors, and also for increased activity of
the downstream MAPK effector pathway (Supplemental Figure
S2 and Supplemental Table S1). Overall, we observed a sur-
prising degree of heterogeneity in the expression patterns of
key signaling components in invasive and metastatic lesions,
with less variability across the spectrum of PanIN lesions (Sup-
plemental Figure S2 and not shown). More precisely, we ob-
served discrete types of heterogeneity that spanned stages of
progression and states of differentiation, and which even mani-
fested stochastically across individual lesions of similar differ-
entiation within the same tissue. For example, intense focal
Errb1/Egfr expression was seen in some cells of PanINs, but
not others, against the backdrop of more diffusely positive
PanIN cells (Supplemental Figure S2E). Only very weakly posi-472tive expression of Erbb1/Egfr was observed in primary invasive
carcinomas, regardless of differentiation state; finally, metasta-
ses uniformly lacked such expression. Thus, Erbb1/Egfr ex-
pression manifested principally progression-stage-dependent
heterogeneity. In comparison, Erbb2/Her2 was invariably and
intensely expressed in PanIN lesions (Supplemental Figure
S2F). Moreover, high levels of expression were maintained, for
the most part, in the invasive carcinomas (Supplemental Figure
S2J) and the metastases (Supplemental Figures S2N and S2R).
Nevertheless, there were discrete regions within both primary
tumors (Supplemental Figure S2J) and among distinct meta-
static lesions in a given organ that displayed significant hetero-
geneity. Thus, in some cases, regions of well-differentiated
PDA strongly expressed Erbb2/Her2, while more poorly dif-
ferentiated areas were less robust, a form of differentiation-
state-dependent heterogeneity. However, there were also
glandular liver metastases that showed intense levels of ex-
pression, while others were completely lacking (Figures 3I–3L),
a stochastic form of heterogeneity. Thus, the pattern of Erbb2/
Her2 in invasive and metastatic disease was complex and not
predictable even within a given animal, consistent with the
heterogeneous nature of Erbb2/Her2 expression in human pan-
creatic cancer (Day et al., 1996). Interestingly, activation of the
MAPK pathway, as assessed by phosphorylated Erk (pErk)
levels, correlated highly with Erbb2/Her2 expression (Supple-CANCER CELL : MAY 2005
A R T I C L EFigure 2. LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice succumb to invasive and widely metastatic pancreatic ductal adenocarcinoma (PDA)
A–F: Gross pathological photographs of metastatic PDA in a representative series of triple mutant mice. A: Abdominal distension due to the accumulation
of malignant ascites was commonly noted. B: Primary PDA in the head-of-the-pancreas (asterisk) resulting in the distended loop of the small bowel due
to direct invasion and compression of the proximal duodenum (arrow); also note biliary obstruction and gallbladder distension (outlined). C: Gallbladder
distension due to a pancreatic tumor in the head (unlabeled); diffuse nodularity was noted in the tail (t) of the pancreas. D and E: Specimens from same
mouse demonstrating multiple gross hepatic (black arrows) and diaphragmatic metastases (white arrowheads) and a large head-of-the-pancreas primary
tumor (asterisk). F: Multiple pleural metastases (arrowheads).
G–O: Histological features in LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice. G: PanIN-1A lesion in a 4-month-old triple mutant mouse (400×). H–J: Well-
differentiated glandular PDA (H) (200×) and well-differentiated liver metastasis (I) (100×) in a 4.5-month-old animal. The liver metastasis highly expressed
the ductal marker, CK-19 (J) (400×). K and L: 8-month-old mouse with well-differentiated lung metastasis (K) (200×) demonstrating CK-19 expression (L)
(200×). M–O: Ductal adenocarcinoma from 3-month-old mouse with both well-differentiated (arrows) and surrounding poorly differentiated areas (M)
(200×). The abundant mucin content of well-differentiated areas is revealed by Alcian blue staining (N) (arrows, 200×), while CK-19 expression confirms
their ductal phenotype (O) (arrows, 400×).mental Figures S2G, S2K, S2O, and S2S), but much less highly
with Erbb1/Egfr (with a few exceptions—see, for example,
Supplemental Figures S2J and S2K). To the extent that activa-
tion of the MAPK pathway is important for pathogenesis, there-
fore, Erbb2/Her2 may represent a better therapeutic target.
Aberrant expression of Sonic hedgehog (Shh), a member ofCANCER CELL : MAY 2005the Hedgehog ligand family, has recently been described in
both preinvasive and invasive human PDA and suggested as a
novel therapeutic target (Berman et al., 2003; Thayer et al.,
2003). Expression of Shh is normally inhibited during develop-
ment to allow proper pancreatogenesis from endodermal
structures that are otherwise biased toward intestinal and he-473
A R T I C L EFigure 3. Molecular heterogeneity of signaling pathways
A–D: Heterogeneity in E cadherin expression as a function of degree of differentiation. A: Membranous staining of E cadherin in normal acinar cells (white
arrow) and PanIN-1A (black arrow, 400×). B: 4.5-month-old mouse with intense E cadherin staining in the well-differentiated areas of a primary PDA (arrows),
but not in the poorly differentiated areas (asterisk, 200×). C and D: Liver metastases from the same mouse as in B, demonstrating lack (C, asterisk) or
presence (outlined in D) of E cadherin staining, depending on the degree of differentiation. Normal hepatic parenchyma (h) is also denoted (200×).
E–H: Stochastic heterogeneity demonstrated by Her2 expression in primary PDA from a 4.5-month-old mouse. H&E (E) (40×) and immunohistochemical
detection of Her2 (F) (40×) demonstrate a large, invasive PDA with high levels of Her2 expression in one area (right box, magnified in H, 200×) and essentially
no expression in another (left box, magnified in G, 200×). The latter area shows significant Her2 expression in PanINs (G, arrows), but lack of expression in
adjacent normal acinar tissue (ac) and the moderately differentiated PDA (asterisk).
I–L: Stochastic heterogeneity of Her2 expression in liver metastases. I: H&E (40×) and Her2 immunohistochemistry (J) in serial section demonstrates multiple
liver metastases (outlined) but only one area of Her2-positive staining (J, 40×). Higher magnification of the Her2-positive (arrow, K, 200×) and Her2-negative
(asterisk, L, 200×) liver metastases.patic fates. We found Shh to be aberrantly and highly ex-
pressed in both preinvasive (Supplemental Figure S2H) and in-
vasive murine PDA (Supplemental Figure S2L), and at least
moderately expressed in metastases (Supplemental Figures
S2P and S2T), representing a consistent pattern across dis-
ease progression.
Finally, expression of E cadherin, a member of the integrin
family of adhesion molecules, also displayed impressive and
unexpected variability. Loss of E cadherin expression has been
implicated in the epithelial-to-mesenchymal transition (EMT)
thought to precede the development of an invasive and meta-
static phenotype, perhaps by altering critical interactions in a
structured epithelium (Cavallaro and Christofori, 2004). In addi-
tion, E cadherin may suppress cellular transformation by se-
questering β-catenin and preventing its translocation to the
nucleus (Gottardi et al., 2001). As expected, E cadherin expres-
sion was demonstrable in normal acini and preinvasive ductal
lesions (Figure 3A). In pancreatic ductal tumors, expression
was robust in the more differentiated regions and much less so
in the more poorly differentiated regions, consistent with a role
in disease progression (Figure 3B). This same pattern of ex-474pression persisted in metastases, however, where once again
robust levels were observed in well-differentiated metastases
(Figure 3D), but not in poorly differentiated lesions (Figure 3C)
in the same organ. If we consider each metastasis to represent
an independent and clonal event, then this example encom-
passes both stochastic and differentiation-state heterogeneity.
Requirements for disease progression
We wondered whether combinations of additional mutations
in critical tumor suppressor gene pathways might explain the
striking degree of molecular heterogeneity in the primary tu-
mors and metastases of LSL-KrasG12D/+;LSL-Trp53R172H/+;
Pdx-1-Cre mice. To assess this possibility directly, we investi-
gated primary cell lines established from ductal cells at various
stages of disease progression using methods we described
recently (Schreiber et al., 2004). Portions of each resected
specimen from wild-type, LSL-KrasG12D/+;Pdx-1-Cre, and LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre animals were preserved
in parallel for histologic analysis. The recovered cells were pas-
saged a total of four to five times on discrete matrices to favor
the growth of ductal elements over other cellular componentsCANCER CELL : MAY 2005
A R T I C L EFigure 4. Uniform loss of wild-type Trp53 and lack of mutations in additional tumor suppressor genes in primary PDAs and metastases
A: Activated mutant (1 LoxP, upper band) and wild-type (lower band) Kras alleles are present in early passage cell lines prepared from matched sets of
primary carcinomas and metastases. LSL-Kras ductal cells were prepared from LSL-KrasG12D/+ animal. Preinvasive cell line was prepared from LSL-KrasG12D/+;
Pdx-1-Cre animal. Control DNA was prepared from MEFs that had (+) or had not (−) recombined the conditional allele.
B: Wild-type Trp53 allele is consistently lost (lower band) in all primary tumors and metastases.
C–H: Immunohistochemical assessment of Trp53 levels in tumors from triple mutant mice. C and D: p53 expression in PanIN lesions is absent (arrow) or
weakly positive (open arrow), whereas intense expression of Trp53 (arrowheads) is noted in the adjacent invasive component of PDA (C, 100×) (D, 400×).
E and F: Absent (arrow) or weak (open arrow) expression of Trp53 in PanINs, but intense expression (arrowheads) in invasive PDA cells (E, 200×) (F, 400×).
G and H: Intense expression (arrowheads) of Trp53 in a primary PDA (G, 400×) and liver metastasis (H, 400×) from the same animal.
I: Expression of critical tumor suppressors in a representative panel of control, preinvasive, invasive, and metastatic cell lines. Note that Trp53 levels are
highest in cell lines that have lost the wild-type allele.
J: Functional interaction of p16Ink4a and Cdk4 in control, preinvasive, invasive, and metastatic cell lines. Top panel: p16Ink4a levels in the lysates of cell lines
(arrow denotes the migration of p16Ink4a). Second panel: Cdk4 immunoprecipitation followed by p16 immunoblotting demonstrates coimmunoprecipita-
tion of the two proteins. Third panel: Cdk4 levels in lysates. Bottom panel: Cdk4 levels in the Cdk4 immunoprecipitates. Bars over adjacent lanes indicate
samples prepared from the same animal.of the pancreas and stroma. These procedures result in essen-
tially uniform populations of ductal or tumor cells as assessed
by light microscopy (Supplemental Figures S3A–3E) and bio-
chemical assays (Schreiber et al., 2004). We note that ductal
cells from LSL-KrasG12D/+;Pdx-1-Cre mice contain a mixture of
cells at different PanIN stages; it is also formally possible that
a rare “invasive” cell may be copurified. However, by a number
of criteria detailed below, LSL-KrasG12D/+;Pdx-1-Cre ductalCANCER CELL : MAY 2005cells clearly demonstrated properties reflecting an earlier stage
of progression than their invasive counterparts. Thus, for simplic-
ity, we refer to these cells interchangeably as LSL-KrasG12D/+;
Pdx-1-Cre or preinvasive ductal cells.
We first established the genetic status of the Kras and Trp53
loci in a panel of primary control, preinvasive, and tumor cell
lines. Rearrangement, or activation, of the LSL-KrasG12D allele
was seen in preinvasive and tumor cell lines, as expected, to-475
A R T I C L Egether with the presence of the wild-type Kras allele (Figure
4A). Resected pancreatic tissue from a 6-week-old LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mouse demonstrated
activation of the Trp53R172H allele along with retention of the
wild-type Trp53 gene (not shown). Each one of the primary
pancreatic tumor cell lines, as well as all of the metastatic cell
lines, similarly revealed the presence of the activated point mu-
tant Trp53 allele; however, in every instance, the wild-type al-
lele was lost (Figure 4B). This combination of point mutation
and loss of heterozygosity (LOH) of Trp53 is also the principal
way in which mutations in this TSG manifest themselves in hu-
man pancreatic cancer (Rozenblum et al., 1997; Scarpa et al.,
1993). Thus, it would appear that LOH is a requisite step in
tumor progression in the setting of Trp53R172H. Indeed, the im-
munohistochemical assessment of Trp53 expression in vivo
provides further evidence of LOH as a key step in progression.
In normal cells, steady-state levels of the Trp53 tumor suppres-
sor lie below the detection limits of conventional immunoblot
and immunohistochemical methods. The specific point muta-
tions associated with tumorigenesis, however, confer in-
creased stability on the protein and enable detection. In ani-
mals with germline transmission of the Trp53R172H allele, for
example, normal tissues retain the wild-type allele, and Trp53
is not detected immunohistochemically; however, in the tumors
that developed in these animals with demonstrated LOH, Trp53
expression was readily detectable (Olive et al., 2004). Thus, the
absence of detectable Trp53 expression in PanIN lesions adja-
cent to invasive carcinomas (Figures 4C–4F) suggests retention
of the wild-type allele and, therefore, a largely intact rate of
protein degradation. Occasional PanINs do show moderate, or
intermediate, levels of detectable Trp53, potentially suggesting
early loss of the wild-type allele or activation of additional
mechanisms of p53 stabilization (Figure 4F). Intense expres-
sion of Trp53 is seen only in the invasive cancers and metasta-
ses, consistent with LOH at the wild-type locus (Figures 4C–4H).
As a first step toward evaluating the integrity of other key
tumor suppressor pathways, we performed immunoblot analy-
ses of whole-cell lysates on a representative sampling of con-
trol, preinvasive, and tumor cell lines. As expected, Trp53 ex-
pression was not discernible in either wild-type or preinvasive
LSL-KrasG12D/+;Pdx-1-Cre ductal cells; demonstrable levels
were seen in the primary and metastatic tumor cell lines from
LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre animals, consis-
tent with expression of the activated point mutant allele (Figure
4I). Smad4 expression, an integral component of the TGFβ
pathway, was uniformly present. Somewhat to our surprise, we
found that all of the cancer cell lines also retained expression
of the p16/Ink4a tumor suppressor (Figure 4I) and the p19/Arf
tumor suppressor (not shown). Expression of other proteins of
potential importance in pancreatic cancer, including Rb, Akt,
and Myc, was similarly intact and not significantly different
among the various cell lines analyzed (Supplemental Figure S4).
The Cdkn2/Ink4a pathway can be inactivated by homozy-
gous deletion of the locus, by monoallelic deletion coupled
with an inactivating point mutation in the remaining allele, or,
less frequently, by promoter methylation resulting in epigenetic
silencing (Caldas et al., 1994; Schutte et al., 1997). In addition,
specific point mutation of its cellular target, Cdk4, can inhibit
the interaction between these two proteins. Thus, the func-
tional integrity of the Cdkn2/Ink4a axis can be demonstrated
by the ability of the tumor suppressor to bind Cdk4, which cor-476relates with inhibition of its kinase activity. Protein lysates from
primary ductal cells, preinvasive cells and tumor cells con-
tained comparable amounts of Cdk4 and variable, though al-
ways detectable, levels of Cdkn2/Ink4a (Figure 4J). Importantly,
the binding between Cdkn2/Ink4a and Cdk4 was always re-
tained, as manifested by the ability to coimmunoprecipitate the
two proteins.
The integrity of the TGFβ-Smad4 tumor suppressor pathway
in these cell lines, from surface receptor binding of ligand to
activation and nuclear translocation of intracellular Smad2/3/4
complexes, was assessed by following the intracellular local-
ization of Smad4 before and after treatment with TGFβ. In pre-
invasive, primary carcinoma, and metastatic cells, diffusely dis-
tributed Smad4 was efficiently translocated to the nucleus in
response to TGFβ, demonstrating that the pathway was intact
(Supplemental Figure S5).
As a final method of interrogating the fidelity of these critical
pathways, we directly sequenced the open reading frames for
Cdkn2/Ink4a, Cdk4, and Smad4. Several steps were taken to
ensure faithful rendering of the sequences and to minimize the
introduction of artifacts. First, cDNA was reverse-transcribed
from total RNA preparations of the various cell lines and then
amplified by PCR. Single bands of the correct molecular weight
were recovered in all circumstances. The isolated cDNAs were
then subcloned and eight independent clones for each cell line
were sequenced bidirectionally. A mutation was considered
significant only if: (1) it was detected in both strands of a given
clone (to obviate potential sequencing artifacts) and (2) the
same mutation appeared in more than one of eight clones (i.e.,
R25%), to avoid potential errors introduced by PCR. Very few
mutations of any kind were discovered by this method and, by
the exclusion criteria noted, no reproducible mutations were
found in Cdkn2/Ink4a, Cdk4, or Smad4. As a further test of the
methodology, we isolated and sequenced 5 subclones each
for both Kras2 and Trp53 from five tumor and two control cell
lines. In all cases, at least two or three of the sequenced clones
from each tumor cell line revealed the presence of the KrasG12D
point mutant allele, while the remaining clones contained the
corresponding wild-type alleles. In contrast, every clone from
each of the five tumor cell lines showed only the presence of
the Trp53R172H mutation and no wild-type Trp53 sequence,
consistent with LOH. Wild-type cells contained only wild-type
alleles for both genes in all clones, while in preinvasive ductal
cells from LSL-KrasG12D/+;Pdx-1-Cre animals, we detected
both mutant and wild-type Kras alleles, but only wild-type
Trp53, as expected. Thus, LOH in the setting of Trp53R172H was
an invariant event in pancreatic tumor progression and, by sev-
eral different methodologies, no mutations in the other princi-
pal tumor suppressor gene pathways were apparent.
Genomic instability
A pathognomonic feature of human PDA is its high degree of
genomic, principally chromosomal, instability. Chromosomal
instability (CIN), manifested by simple aneuploidy or by com-
plex structural abnormalities, would provide a ready explana-
tion for the molecular heterogeneity observed in the primary
carcinomas and metastases noted above. Wholesale gains or
losses of chromosomes are associated with centrosomal
amplification and subsequent chromosomal missegregation,
known sequelae of Trp53 deficiency (Tarapore and Fukasawa,
2002). We therefore first examined isolated tumor cell lines forCANCER CELL : MAY 2005
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sometimes involving as many as 30 identifiable centrosomes
per cell, was uniformly observed in primary carcinoma and
metastatic cell lines (Figures 5A and 5B). On average, at least
one or two cells with increased centrosomes were observed
per high-power field. LSL-KrasG12D/+;Pdx-1-Cre cells, however,
only rarely contained more than one or two centrosomes (Fig-
ure 5C).
The existence of CIN in vivo can be inferred from the pres-
ence of anaphase bridges (AB), which presumably occur when
di- or multicentric chromosomes attempt to enter anaphase
and are trapped between opposing forces from the two spindle
poles. The inevitable resulting break in the chromatin sets the
stage for another end-to-end fusion event. Such repeated
breakage-fusion-bridge cycles are thought to represent the pri-Figure 5. Chromosomal instability in Pdx-1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice
A–F: Centrosome amplification in pancreatic carcinoma cell lines. Pancreatic cell lines prepared from primary PDA (A and B, 60×) and liver metastases
(C and D, 60×) of triple mutant mice frequently contain greater than two centrosomes as demonstrated by γ-tubulin staining (A and C red dots), whereas
pancreatic cell lines prepared from Pdx-1-Cre;LSL-KrasG12D/+ mice have a normal number of centrosomes (E and F 40×). α-tubulin staining (green, B, D,
and F) reveals the abnormal mitotic spindles in carcinoma cell lines in comparison to the normal spindles of LSL- KrasG12D/+;Pdx-1-Cre;cells. Cells were also
stained with DAPI (blue).
G–I: Anaphase bridges are common in triple mutant animals. G: Abundant anaphase figures in murine PDA (boxes, 40×) demonstrate classic bridges
(arrows) (H and I, 400×).
J: Abnormal anaphase that does not meet strict criteria for designation as anaphase bridge (400×).
K and L: Abnormal mitotic figures in tumor sections (400×).
M and N: Nuclear bridges in primary cell lines prepared from two separate PDAs (400×).CANCER CELL : MAY 2005mary driving force behind the large-scale CIN associated with
human epithelial carcinogenesis (Lengauer et al., 1997; Len-
gauer et al., 1998). We found a large number of AB (Figures
5G–5I) and highly abnormal mitotic figures (Figures 5K and 5L)
in our survey of primary pancreatic carcinomas, and even oc-
casionally noted more than one AB in a single low-power field
(Figure 5G). In a total of 171 anaphase figures evaluated (5–30
per tumor) from 13 primary tumors, 67 (2–12 per tumor) met
strict criteria for anaphase bridges, revealing an overall ana-
phase bridge index of 39% (range 20%–40%). This value is
comparable to that seen in human PDA (17%) (Montgomery et
al., 2003) and implies a very high degree of chromosomal insta-
bility.
Finally, direct assessments of chromosomal structure as a
function of disease evolution were performed. Immunofluores-477
A R T I C L Ecence of nuclei in isolated tumor cell lines revealed the pres-
ence of nuclear bridges (Figures 5M and 5N), the presumptive
correlate of anaphase bridges seen by light microscopy. The
banding patterns of metaphase chromosomes from a large
series of preinvasive and carcinoma cell lines were subse-
quently analyzed. Each of the malignant cell lines contained
significant chromosomal aberrations and fusion events and,
importantly, the vast majority (n = 12/14) contained nonrecipro-
cal translocations (NRT), a hallmark of CIN (Table 2). In addi-
tion, these cells were markedly aneuploid. In comparison, the
majority of LSL-KrasG12D/+ and LSL-KrasG12D/+;Pdx-1-Cre duc-
tal cells were diploid with relatively few chromosomal aber-
rations.
To determine if particular translocations predominated in the
carcinomas and metastases, we performed spectral karyotyp-
ing on a number of primary cell lines from pancreatic carcino-
mas and associated metastases (Table 2 and Figure 6). Clonal
NRTs were discovered in 3 of the 8 carcinoma cell lines exam-
ined, and chromosome 6, which notably contains Kras, was
overrepresented in 6 of these 8 lines. Finally, the spectral
karyotypes of a number of metastases revealed completely
distinct genomic abnormalities when compared with their par-
ent primary pancreatic cancers, consistent with dissemination
of metastatic cells early in disease evolution.
The laboratory mouse is relatively resistant to the develop-Table 2. Cytogenetic analyses of primary control, preinvasive, invasive, and metastatic ductal cell lines
Cell line
Chromosomal Chromatid Chromosome Chromosome p:p q:q fusions
IDa Description n % diploid aberrations breaks fragments fusions fusions (dicentrics) Markersb Clonal abnormalitiesc
A normal PDC 36 55.6 8.3 2.8 5.6 2.8 0 2.8 0 ND
B Preinvasive 38 65.8 18.4 2.6 13 2.6 2.6 0 0 2–4 copies all
chromosomes
C PDA 33 3 97 24 100 24.2 12 15 3 5–6 copies chrom 6, 3–5
copies Y
D PDA 30 0 100 13.3 96.7 96.7 0 0 96.7 t(1;11;10;1), t(4;1), chrom
4 & 15 fragments
E PDA 35 37.1 25.7 8.6 17.1 8.6 5.7 2.9 0 ND
F PDA 31 0 96.8 12.9 90.3 32.2 29 0 9.7 ND
G PDA 31 6.4 93.5 9.7 90.3 9.7 6.4 0 3.2 ND
H PDA 31 3.2 96.8 22.6 96.8 32.2 16.1 9.7 0 ND
I-1 PDA 30 0 100 0 93 90 20 0 86.7 t(15;15) x 2; t(12;X), t(8;2);
6–12 copies of
chromosomes
2,6,7,12,15
I-2 Liver 30 0 100 7 100 53.3 13 3 33.3 2-5 copies all
metastasis chromosomes
J-1 PDA 33 30.3 30.3 3 21.2 9.1 3.03 3.03 3.03 ND
J-2 Liver 33 0 100 39.4 90.9 42.4 18.2 12.1 18.2 6–10 copies all
metastasis chromosomes
J-3 Ascites 33 30.3 60.6 24.2 48.5 33.3 18.2 9.1 12.1 3–6 copies chromosome 6
K-1 PDA 33 30.3 69.7 6.1 63.6 24.2 9.1 0 18.2 t(7;17), 6 copies
chromosome 2; 5–13
copies of chromosome
13
K-2 Liver 36 36.1 36.1 2.8 16.7 25 13.9 13.9 5.6 3–12 copies all
metastasis chromosomes
Liver
K-3 metastasis 35 42.9 31.4 8.6 31.4 20 17.1 2.9 2.9 ND
aCell lines with a shared letter identification were isolated from the same animal.
bPercentage of metaphases that contain a marker chromosome(s), the result of a nonreciprocal translocation.
cClonal abnormalities assessed by SKY refer to gain of chromosomes in at least 2 metaphases or loss of specific chromosomes in at least 3 metaphases (out of
10 examined).478ment of CIN and, in particular, structural abnormalities such as
inversions, deletions, and nonreciprocal translocations. Murine
chromosomes are distinguished by inordinately long telomeres
as compared with their human counterparts. Indeed, this differ-
ence has been thought to preclude the development of suffi-
cient telomere attrition to drive genomic instability, and has
therefore been offered as an explanation for the propensity to-
ward hematologic and mesenchymal malignancies in mice at
the expense of the more karyotypically complex epithelial tu-
mors common in humans (Rangarajan and Weinberg, 2003).
The high degree of CIN observed in LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre mice therefore prompted us to exam-
ine whether telomere erosion had somehow contributed. We
found that the chromosomes from these animals contained in-
tense telomeric signals by PNA-FISH, suggesting the presence
of significant telomeric sequence (Figures 5O–5Q). Moreover,
the chromosomal fusion points also contained significant telo-
meric signals, demonstrating that these aberrant events can
occur in the setting of preserved telomeric length.
Discussion
Understanding the genetic requirements for the initiation and
progression of pancreatic ductal adenocarcinoma is a neces-
sary first step toward the development of specific detectionCANCER CELL : MAY 2005
A R T I C L EFigure 6. Nonreciprocal translocations and pre-
served telomeres in pancreatic cancer cell lines
from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre
mice
A–C: SKY analysis (A and C) of PDA cell line I-1
demonstrates four clonal nonreciprocal translo-
cations (NRTs), including two different NRTs of
chromosome 15 (t[15;15] “long” and t[15;15]
“short”) as well as t(X;12) and t(8;2). Geimsa
stain of the metaphase spread (B) demon-
strates the marker chromosomes (arrows).
D–F: Spectral karyotype analysis (SKY) (D and F)
of ductal carcinoma cell line demonstrates two
recurrent nonreciprocal translocations, t(1;11;10;1)
and t(4;11) (arrows) (cell line D in Table 2). The
corresponding Giemsa image (E) for D is also
shown, demonstrating the marker chromo-
somes (arrows).
G–I: Preserved telomeric sequence at chromo-
somal ends and fusion points in carcinoma cells.
G and H: Normal metaphase spreads and PNA-
FISH of telomeres typical of LSL-KrasG12D/+ pri-
mary pancreatic ductal cells (G) and LSL-
KrasG12D/+;Pdx-1-Cre preinvasive ductal cells
(H). I: Preserved telomeres and strong telomeric
signal at the sites of p-p arm fusions (f) in an in-
vasive carcinoma cell line of a triple mutant
mouse.and therapeutic modalities. The assembled compendium of
molecular changes that appear to chronicle human pancreatic
tumorigenesis has provided important clues to mechanisms of
disease pathogenesis. As part of a systematic effort to eluci-
date the requisite elements for disease progression and their
biologic consequences, we have genetically engineered spe-
cific mutations suggested by these data into the endogenous
loci of the mouse genome. We have shown here that targeted
physiologic expression of point mutant Trp53 promotes the de-
velopment of invasive and widely metastatic PDA from preinva-
sive disease initiated by KrasG12D. The resultant disease faith-
fully recapitulates the clinical syndrome, histopathology, and
metastatic profile of the cognate human condition. Disease
progression from preinvasive to invasive disease involved loss
of the wild-type Trp53 allele, a nearly invariant feature of human
pancreatic cancers that harbor point mutations in this gene.
The primary and metastatic lesions seen in these animals man-
ifested a high degree of chromosomal instability, another ge-
netic hallmark of the human disease. Moreover, the develop-
ment of nonreciprocal translocations and other chromosomal
aberrations occurred in the presence of preserved telomere se-
quence, suggesting that Trp53R172H and KrasG12D expression
promotes such events independently of telomere erosion. Fi-
nally, no mutations or functional defects in either the p16Ink4a
or TGFβ-Smad4 tumor suppressor pathways were discoveredCANCER CELL : MAY 2005in primary carcinoma or metastatic cells, suggesting that con-
comitant endogenous Trp53R172H and KrasG12D expression de-
fines a unique genetic pathway to invasive and metastatic pan-
creatic ductal adenocarcinoma.
Distinct genetic pathways to pancreatic
ductal adenocarcinoma
We have previously shown that endogenous expression of
KrasG12D is sufficient to initiate pancreatic tumorigenesis (Hin-
gorani et al., 2003). Concomitant expression of KrasG12D with
Trp53R172H or with biallelic deficiency of Ink4a/Arf leads to pro-
foundly distinct phenotypes, including latency to tumor pro-
gression, survival, presence of macrometastatic disease, and
histological morphology. LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-
1-Cre animals have a median survival of approximately 5
months, manifest widely metastatic pancreatic ductal adeno-
carcinoma that recapitulates the human spectrum, and show
predominantly glandular histology, consistent with their desig-
nation as adenocarcinomas. By comparison, LSL-KrasG12D/+;
Ink4a/Arf(flox/flox);Pdx-1-Cre animals (Aguirre et al., 2003) have
a greatly curtailed median survival of approximately 8 weeks,
develop primarily locally invasive disease, and show a promi-
nent spindle cell or sarcomatoid histology, a rare phenotype in
human pancreatic cancer (albeit evaluated in a limited number
of specimens in direct comparisons [R.H.H. et al., unpublished479
A R T I C L Edata]). In either experimental system, additional mutations in
the respective remaining critical tumor suppressor pathways
were not observed, suggesting that mutation of either Trp53 or
the combined Ink4a/Arf loci is sufficient to induce invasive can-
cer in the setting of endogenous KrasG12D expression.
LOH at the wild-type Trp53 locus was an invariant event in
the primary and metastatic tumors seen in LSL-KrasG12D/+;
LSL-Trp53R172H/+;Pdx-1-Cre animals, as was the development
of widespread chromosomal instability. Thus, a model for
tumor progression involving initiation by KrasG12D and pro-
gression through acquisition of Trp53R172H point mutation, fol-
lowed by induction of chromosomal instability and LOH, is
suggested. The development of mutations in the Trp53 path-
way may greatly favor the elaboration of metastatic disease,
while concomitant Ink4a/Arf deletion instead promotes aggres-
sive, locally invasive tumors and infrequent microscopic me-
tastases to the liver. It may be that the rapidity of tumor growth
and lethality in the latter setting precludes sufficient time for
overt metastases to develop, and that expressing KrasG12D in
mice heterozygous for one or both of the Ink4a/Arf tumor sup-
pressor loci would sufficiently slow disease progression to al-
low for the elaboration of macroscopic metastases. We note,
however, that of the three LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-
1-Cre animals that succumbed within a comparable time frame
to LSL-KrasG12D/+;Ink4a/Arf(flox/flox);Pdx-1-Cre mice (i.e., less
than 11 weeks), all developed grossly evident metastases.
Thus, there may indeed be distinct biological sequelae to these
two genetic routes of tumor progression.
It is worthwhile to note that the available information on ge-
netic events in human pancreatic cancer has been gleaned al-
most entirely from resectable carcinomas in patients without
obvious metastatic disease (Hahn et al., 1995; Schutte et al.,
1997). Thus, the nearly universal finding of CDKN2A/INK4A in-
activation, for example, in human pancreatic cancer may be
skewed by the study of a population presenting only with lo-
cally invasive disease, and may not accurately reflect the muta-
tional spectrum occurring in the majority of patients who in-
stead present with metastatic disease. Moreover, many of
these studies have relied on xenografts propagated in nude
mice. Thus, the available information may not entirely reflect
the natural genetic progression of pancreatic cancer.
There are some data from resected human pancreatic ductal
adenocarcinomas that nevertheless suggest the existence of
distinct genetic trajectories to invasive disease. In a study of
signature genetic mutations in 42 human pancreatic ductal ad-
enocarcinomas, all the tumors harbored activating KRASmuta-
tions, consistent with their role as initiating events (Rozenblum
et al., 1997). Only one-third of the carcinomas, however, con-
tained mutations in all three of the tumor suppressor genes
(CDKN2A/INK4A, TP53, and SMAD4) most frequently impli-
cated in human pancreatic cancer. An additional one-third of
the cancers contained mutations in two of the three TSG, while
15% of tumors harbored mutations in only one TSG. Interest-
ingly, in only two of the tumors were mutations restricted to
KRAS and CDKN2A/INK4A, while four were found to have mu-
tations in KRAS and TP53 only. Thus, among tumors harboring
only one TSG mutation in the context of oncogenic KRAS, pair-
ing with a TP53 mutation was at least as common as, if not
more common than, paired inactivation of CDKN2A/INK4A. Fi-
nally, in three of the tumors fully evaluated for mutations at all
three TSG loci in addition to KRAS, only an activating mutation480in the latter was found. Thus, for these tumors, as yet un-
discovered genetic events must exist that underlie disease
progression. No particular associations between biological be-
havior, metastatic potential or survival, and mutational compo-
sition could be delineated, although the sample sizes of each
of the respective combinations may have been insufficient to
reveal such relationships. We have previously described the
spontaneous development of invasive and metastatic pancre-
atic cancers in two of a cohort of 29 mice engineered to ex-
press endogenous KrasG12D alone (Hingorani et al., 2003); the
majority of these animals have now succumbed to pancreatic
ductal adenocarcinoma, with a median survival of approxi-
mately 15 months (S.R.H. and D.A.T., unpublished observa-
tions). It will be of interest to determine whether there are pre-
ferred genetic routes to PDA in vivo and if particular genetic
profiles correspond to definable biological behaviors.
Point mutant TP53 and gain of function
The TP53 tumor suppressor functions as a homotetrameric
complex that transactivates key target genes in response to a
variety of cellular insults, resulting in cell cycle arrest or apopto-
sis (Kastan et al., 1991; Kern et al., 1991; Prives, 1998). The
importance of TP53 in oncogenesis was initially discerned from
the discovery of point mutant forms of the gene. Indeed, be-
cause selectively mutated and highly expressed forms of the
protein were frequently associated with malignancy, TP53 was
originally thought to be a proto-oncogene that could cooperate
with other oncogenes, notably mutant RAS, to induce trans-
formation (Eliyahu et al., 1984; Parada et al., 1984). Subse-
quent findings led to the suggestion of TP53 as a conventional
tumor suppressor (Finlay et al., 1989; Hinds et al., 1989), and
point mutant forms are now thought to act as dominant nega-
tive components in heterotetramers of wild-type and mutant
proteins. The TP53R175H mutation (Trp53R172H in mice) results
in a partially denatured structure that impairs DNA binding (Cho
et al., 1994).
It remains formally possible that point mutant forms of the
protein actually exhibit a gain of function. According to this
supposition, point mutant Trp53 combined with LOH would not
be functionally equivalent to the homozygous null state. One
postulated mechanism for gain of function of point mutant
Trp53 involves inhibition, through direct binding, of the p53
family members Trp63 and Trp73 (Di Como et al., 1999; Gaid-
don et al., 2001). It is interesting to note in this context that
contrary to virtually all other TSG loci, mutations in TP53 asso-
ciated with human malignancies involve not homozygous loss
of the wild-type genes, but rather point mutation of one allele
followed by LOH at the remaining locus. Heritable cancer pre-
dispositions, such as the Li-Fraumeni syndrome (LFS) involving
“hot spot” mutations in TP53, further substantiate these func-
tional differences (Birch et al., 2001; Kleihues et al., 1997). Not
all such hot spot mutations are phenotypically equivalent, nor
are they necessarily equivalent to the homozygous null state,
as different inherited alleles generate somewhat different tumor
spectra (Olivier et al., 2003). Important differences between
point mutant and homozygous null Trp53 are also manifest in
mice. Trp53−/− mice develop lymphomas and sarcomas almost
exclusively, and succumb between 4–6 months of age (Done-
hower et al., 1992; Jacks et al., 1994). In comparison, carci-
nomas frequently develop in mice with germline expression of
point mutant forms of Trp53, recapitulating the phenotype seenCANCER CELL : MAY 2005
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structural CIN in the setting of point mutant Trp53, in addition
to the more simple numerical instability seen in a Trp53−/−
background, suggest a potential molecular basis for the ob-
served phenotypic gain of function (although formally estab-
lishing this conclusion awaits direct comparison of animals ex-
pressing KrasG12D in the context of point mutant or
homozygous null Trp53). Thus, we can tentatively propose the
following mechanism by which Kras and “oncogenic” Trp53
cooperate to induce tumorigenesis, as initially suggested by
some of the earliest studies of these genes. Kras initiates tu-
morigenesis by expanding a pool of progenitor cells (Hingorani
et al., 2003) which in the context of point mutant Trp53R172H
first acquire LOH at the wild-type Trp53 locus. Indeed, the
presence of the point mutant allele of Trp53 may itself potenti-
ate the chromosomal instability required to develop LOH. LOH
of the wild-type locus then allows for the unfettered elaboration
of chromosomal instability, driving tumor progression through
combinations of widespread translocations, amplifications,
and deletions as shaped ultimately by in vivo selection pres-
sures. In this scenario, Trp53 plays a “caretaker” role in addi-
tion to its usual “gatekeeper” function in cellular and genetic
homeostasis.
Epithelial tumorigenesis in mice and men
The role of genomic instability in tumor progression remains a
subject of intense inquiry and some controversy, with evidence
and opinion divided between essential (Lengauer et al., 1997;
Lengauer et al., 1998) and accessory, or even coincident, roles
(Sieber et al., 2003). On balance, the consensus opinion posits
that widespread CIN generates the genetic repertoire neces-
sary to subvert critical restraints on unregulated growth. Telo-
mere attrition is thought to drive this genomic instability, lead-
ing to a state of global chromosomal aberrations, or “crisis,”
which serves as the final selection barrier through which an
emerging malignant cell must pass (Harley et al., 1994). Seen
in this light, the lack of epithelial carcinomas in genetically en-
gineered mice arguably results from their inordinately long telo-
meres, which in Mus musculus average 40–60 kilobases (kb),
in contrast to the more modest 10 kb of human chromosomes
(Rangarajan and Weinberg, 2003). Indeed, mTert−/− animals
bred for several generations to achieve critically short telo-
meres do develop carcinomas, the occurrence of which is has-
tened in a Trp53+/− background (Artandi et al., 2000). We have
shown here that locally invasive and widely metastatic pancre-
atic ductal adenocarcinoma can be modeled in the experimen-
tal mouse without the direct manipulation of genes involved in
telomere length or structure. Further, these carcinomas pos-
sess complex karyotypes, manifested by chromosomal breaks,
fragments, and fusions. Intriguingly, significant telomeric se-
quence was observed at sites of chromosomal fusions, poten-
tially implicating other mechanisms such as those involved in
uncapping telomeres or otherwise disrupting telomere integrity
(de Lange, 2002; Smogorzewska et al., 2002).
In summary, we have shown here that the initiation of pan-
creatic tumorigenesis by endogenous KrasG12D expression in
the context of Trp53R172H greatly hastens the development of
locally invasive and widely metastatic pancreatic ductal adeno-
carcinoma that faithfully recapitulates all of the extant features
of the human disease. In this model, neither telomere attrition
nor mutation of other major tumor suppressor gene pathwaysCANCER CELL : MAY 2005is required. LOH at the wild-type Trp53 locus is uniformly seen,
along with widespread chromosomal instability, suggesting a
requirement for other, as yet undiscovered, genetic events.
Thus, it appears that at least for the Trp53 and combined Ink4a/
Arf TSG pathways, abrogation of either in the context of onco-
genic Kras is sufficient to induce invasive PDA, albeit with dis-
tinct biological phenotypes. The same may be true for the re-
maining principal tumor suppressor pathway implicated in
pancreatic cancer, namely TGFb-Smad4. Whether various
combinations of mutations confer additional survival advan-
tages or are merely incidental events remains to be deter-
mined. Finally, it will be of interest to perform similar molecular
and genetic analyses on the preinvasive lesions and spontane-
ous tumors that arise in the context of KrasG12D expression
alone (Hingorani et al., 2003) to determine which pathways are
evolutionarily favored for tumor progression, and at what point
significant CIN manifests. The answers to these questions will
likely influence the ability to detect and eradicate this formida-
ble disease.
Experimental procedures
Mouse strains
Conditional LSL-Trp53R172H/+ (Olive et al., 2004), LSL-KrasG12D/+, and Pdx-
1-Cre (Hingorani et al., 2003) strains were interbred to obtain LSL-KrasG12D/+;
LSL-Trp53R172H/+;Pdx-1-Cre triple mutant animals on a mixed 129/SvJae/
C57Bl/6 background. All studies were conducted in compliance with the
University of Pennyslvania IACUC guidelines.
Histological, cytological, molecular, and biochemical analyses
Detailed descriptions for these procedures are provided in the Supplemen-
tal Data.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/5/469/DC1/.
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